The fourth quarter contributed strongly to our overall performance in 2020, with the market approval
for CADScor® from the US Food and Drug Administration (FDA) as the outstanding achievement.
Extract from CEO Per Persson’s message to the End Year Report.
PM_Acarix_Bokslutskommuniké_2020 sv